In Surprise, Placebo, not Aβ Vaccine, Said to Slow Alzheimer’s
AFFiRiS AG claims that a placebo formulation, not their active Aβ vaccine, slowed the progression of Alzheimer's disease in a Phase 2 study.
285 RESULTS
Sort By:
AFFiRiS AG claims that a placebo formulation, not their active Aβ vaccine, slowed the progression of Alzheimer's disease in a Phase 2 study.
The ADCS–PACC, a new cognitive composite test to be used in the A4 prevention trial, detects subtle deficits in older adults with brain amyloid.
Big-data project takes on Alzheimer's with a biomarker computational challenge.
X-ray crystallography reveals secrets of the glutamate receptor.
A new project to identify factors that allow some carriers of pathogenic mutations to escape their genetic destinies could be applicable to neurodegenerative diseases.
A close-up of the protein mayhem within the synaptic bouton offers scientists an unprecedented glimpse of the activity inside.
In award-winning documentary, son traces his mother’s progression into Alzheimer’s disease.
Playing nursemaid, TGF-β helps new neurons in the brain survive, develop, and migrate.
A candidate reference method for measuring Aβ42 in cerebrospinal fluid brings researchers closer to standardization.
People with Alzheimer’s disease and other dementias may benefit from creative activities, but hard studies are still lacking.
An antibody against ApoE helps clear plaques and improves cognition in AD model mice.
New twist to fluorescence-based microscopy lets scientists see up-close how Aβ aggregates in living cells.
Conformations of misfolded tau survive injection from one mouse to the next, a property shared by prions.
MetLife rewards research on secretases, toxic Aβ transmission.
By paring back calcium signaling, researchers prevented signs of Alzheimer’s in mice carrying a presenilin mutation. Could the strategy work in humans?